Introduction {#s1}
============

Soft tissue sarcomas (STS) originate from the mesenchymal lineage, and thus share a similar ancestry [@pone.0015368-Fletcher1]. Despite the fact that the STS group of tumors cover over 50 different histological entities, the occurrence of these tumors amounts to only 0.5% of the annual cancer incidence [@pone.0015368-Fletcher1], [@pone.0015368-Jemal1]. The STSs are among the most aggressive cancer types [@pone.0015368-Jemal1] with a lethality of 40--50%. About 10.000 new cases and 4.000 related deaths were registered in the US in 2009 [@pone.0015368-Jemal1].

Classically STSs have been treated as a single group. This is mainly because the low incidence makes it difficult to conduct decently powered studies on the individual histological entities. With the emerging knowledge of cellular processes and the increasing knowledge about common and uncommon genetic translocations the last decade, it is now clear that the picture might be more intricate. For instance, Ewing family tumors, synovial sarcoma, rhabdomyosarcoma, dermatofibrosarcoma protuberens and others have distinct genetic translocations [@pone.0015368-McArthur1], [@pone.0015368-Sleijfer1], [@pone.0015368-Thway1]. However, the genetic translocations specific for the histological entities have few implications for treatment options. Therefore it is still adequate to group the remaining STSs together under the proposed name of non-gastrointestinal stromal tumor STS (non-GIST STS), although this might change in the future [@pone.0015368-Sleijfer1].

The main treatment of sarcomas is surgical resection, and wide resection margins are considered one of the most important prognostic factors [@pone.0015368-Dickinson1]. However, a considerable variability in prognosis has been observed for subsets of patients with wide resection margins. Consequently, the clinical incorporation of predictive and prognostic molecular biomarkers together with traditional clinical prognostic factors will be pivotal for future management of patients within this large subgroup.

Angiogenesis inhibitors provide a new and exciting therapeutic option for patients with STS [@pone.0015368-Ganjoo1]. However, the angiogenesis pathway in STS needs to be further examined to improve the treatment strategy [@pone.0015368-Ganjoo1].The vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) are well known targets in antiangiogenic treatment. The VEGF super-family consist of six ligands, placental growth factor (PlG), VEGF-A, -B, -C, -D and -E, and three receptors, VEGFR-1, -2 and -3. VEGFR-1 binds PlG and VEGF-A and -B, VEGFR-2 binds VEGF-A, -C and -D and VEGFR-3 binds VEGF-C and -D [@pone.0015368-Tammela1]. VEGF-A signaling through VEGFR-2 is considered the major angiogenic pathway, leading endothelial cells (ECs) to proliferate, sprout and form tubes. VEGFR-1 signaling has been implicated in regulating VEGFR-2 mediated angiogenesis [@pone.0015368-Adams1]. VEGF-C and VEGF-D have been shown to induce lymphangiogenesis through VEGFR-3 [@pone.0015368-Tammela1], [@pone.0015368-Wirzenius1]. The latter has also been implicated in controlling angiogenic sprouting [@pone.0015368-Tammela2].

High levels of VEGF-A in tumors and blood samples from STS patients have previously been associated with higher tumor grade, increased tendency to metastasis, reduced response to treatment, lower overall survival (OS) and increased risk of recurrence [@pone.0015368-Chao1], [@pone.0015368-Yudoh1], [@pone.0015368-Hayes1], [@pone.0015368-Graeven1], [@pone.0015368-Yoon1], [@pone.0015368-DuBois1]. In angiosarcomas, however, high expression of VEGFR-2 has been associated with longer OS [@pone.0015368-Itakura1]. VEGF-C and VEGFR-3 overexpression has also been reported in STSs [@pone.0015368-Friedrichs1].

In this study, the aim was to assess the prognostic impact of VEGF-A, -C, -D and VEGFR-1. -2 and -3 in non-GIST STS patients with wide and non-wide resection margins.

Methods {#s2}
=======

Patients and Clinical Samples {#s2a}
-----------------------------

Primary tumor tissue from anonymized patients diagnosed with non-GIST STS at the University Hospital of North-Norway and the Hospitals of Arkhangelsk county, Russia, from 1973 through 2006, were collected. In total 496 patients were registered from the hospital databases. Of these 247, patients were excluded from the study due to: missing clinical data (n = 86) or inadequate paraffin-embedded fixed tissue blocks (n = 161). Thus 249 patients with complete medical records and adequate paraffin-embedded tissue blocks were eligible.

This report includes follow-up data as of September 2009. The median follow-up was 37.6 (range 0.1--391.7) months. Complete demographic and clinical data were collected retrospectively. Formalin-fixed and paraffin-embedded tumor specimens were obtained from the archives of the Departments of Pathology at the University Hospital of North-Norway and the Hospitals of Arkhangelsk County. The tumors were graded according to the French Fédération Nationale des centres de Lutte Contre le Cancer (FNCLCC) system and histologically sub typed according to the World Health Organization guidelines [@pone.0015368-Fletcher1], [@pone.0015368-Guillou1]. Wide resection margins were defined as wide local resection with free microscopic margins or amputation of the affected limb or organ. Non-wide resection margins were defined as marginal or intralesional resection margins, or no surgery.

Microarray construction {#s2b}
-----------------------

All sarcomas were histologically reviewed by two trained pathologists (S. Sorbye and A. Valkov) and the most representative areas of tumor cells (neoplastic mesenchymal cells) were carefully selected and marked on the hematoxylin and eosin (H/E) slide and sampled for the tissue microarray (TMA) blocks. The TMAs were assembled using a tissue-arraying instrument (Beecher Instruments, Silver Springs, MD). The Detailed methodology has been previously reported [@pone.0015368-Donnem1]. Briefly, we used a 0.6 mm diameter stylet, and the study specimens were routinely sampled with four replicate core samples from different areas of neoplastic tissue. Normal tissue from the patients was used as staining control.

To include all core samples, 12 TMA blocks were constructed. Multiple 5-µm sections were cut with a Micron microtome (HM355S) and stained by specific antibodies for immunohistochemistry (IHC) analysis.

Immunohistochemistry {#s2c}
--------------------

The applied antibodies were subjected to in-house validation by the manufacturer for immunohistochemical analysis on paraffin-embedded material. The antibodies used in the study were as follows: VEGF-A (1∶10, rabbit polyclonal; RB-1678; Neomarkers), VEGF-C (1∶25, rabbit polyclonal; 18-2255; Zymed Laboratories), VEGF-D (1∶40, mouse monoclonal; MAB286; R&D Systems), VEGFR-1 (1∶10, rabbit polyclonal; RB-1527; Neomarkers), VEGFR-2 (1∶25, rabbit polyclonal; RB-9239; Neomarkers), and VEGFR-3 (1∶10, rabbit polyclonal; Sc-321; Santa Cruz Biotechnology).

Sections were deparaffinized with xylene and rehydrated with ethanol. Antigen retrieval was done by placing the specimen in 0.01 mol/L of citrate buffer at pH 6.0 and exposed to repeated (twice) microwave heating of 10 min (except VEGFR-3, twice for 5 min) at 450 W. VEGF-D was heated for 45 min in a water bath in 0.01 mol/L of citrate buffer. The DAKO EnVision+ System-HRP kit (diaminobenzidine) was used for endogen peroxidase blocking. As negative staining controls, the primary antibodies were replaced with the primary antibody diluents. Primary antibodies were incubated for 30 min in room temperature (except VEGFR-3, 20 min, and VEGF-D, overnight at 4°C). The DAKO EnVision+ System-HRP kit (diaminobenzidine) was used to visualize the antigens. This was followed by the application of liquid diaminobenzidine and substrate-chromogen, yielding a brown reaction product at the site of the target antigen. Finally, all slides were counterstained with hematoxylin to visualize the nuclei. For each antibody, included negative staining controls, all TMA staining were done in a single experiment.

Scoring of immunohistochemistry {#s2d}
-------------------------------

The ARIOL imaging system (Genetix, San Jose, CA) was used to scan the slides of antibody staining of the TMAs. The slides were loaded in the automated slide loader (Applied Imaging SL 50) and the specimens were scanned at low resolution (1.25×) and high resolution (20×) using the Olympus BX 61 microscope with an automated platform (Prior). Representative and viable tissue sections were scored manually on computer screen semi quantitatively for cytoplasmic staining. The dominant staining intensity was scored as: 0 =  negative; 1 =  weak; 2 =  intermediate; 3 =  strong. All samples were anonymized and independently scored by two trained pathologists (A. Valkov and S. Sorbye). When assessing a variable for a given core, the observers were blinded to the scores of the other variables and to outcome. Mean score for duplicate cores from each individual was calculated separately.

High expression in tumor cells was defined as score ≥1.5 (VEGF-A, VEGF-D, VEGFR-1-3) and ≥1 (VEGF-C) ([Fig. 1](#pone-0015368-g001){ref-type="fig"}).

![IHC analysis of TMA of non-GIST STSs representing different scores for tumor cell VEGF-C and VEGFR-3.\
(A) Tumor cell VEGF-C high score in leiomyosarcoma; (B) Tumor cell VEGF-C low score in leiomyosarcoma; (C) Tumor cell VEGFR-3 high score in undifferentiated pleomorphic sarcoma; (D) Tumor cell VEGFR-3 low score in liposarcoma. Abbreviations: IHC, immunohistochemistry; non-GIST STS, non-gastrointestinal stromal tumor soft-tissue sarcoma TMA, tissue microarray; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.](pone.0015368.g001){#pone-0015368-g001}

Statistical Methods {#s2e}
-------------------

All statistical analyses were done using the statistical package SPSS (Chicago, IL), version 16. The IHC scores from each observer were compared for interobserver reliability by use of a two-way random effect model with absolute agreement definition. The intraclass correlation coefficient (reliability coefficient) was obtained from these results. The Chi-square test and Fishers Exact test were used to examine the association between molecular marker expression and various clinicopathological parameters. Univariate analyses were done using the Kaplan-Meier method, and statistical significance between survival curves was assessed by the log rank test. DSS was determined from the date of diagnosis to the time of cancer related death. To assess the independent value of different pretreatment variables on survival, in the presence of other variables, multivariate analyses were carried out using the Cox proportional hazards model. Only variables of significant value from the univariate analyses were entered into the Cox regression analyses. Probability for stepwise entry and removal was set at .05 and .10, respectively. The significance level used for all statistical tests was P\<0.05.

Ethical clearance {#s2f}
-----------------

The National Data Inspection Board and The Regional (Northern Norway) Committee for Research Ethics approved the study.

Results {#s3}
=======

Clinopathological Variables {#s3a}
---------------------------

The clinopathological variables are summarized in [Table 1](#pone-0015368-t001){ref-type="table"}. The median age was 59 (range 0--91) years, 56% were female, 167 patients were Norwegian and 82 Russian. The Non-GIST STSs comprised 249 tumors including angiosarcoma (n = 13), fibrosarcoma (n = 20), leiomyosarcoma (n = 64), liposarcoma (n = 34), undifferentiated pleomorphic sarcoma (n = 58), neurofibrosarcoma/malignant peripheral nerve sheath tumor (MPNST, n = 11), rhabdomyosarcoma (n = 16), synovial sarcoma (n = 16) and unspecified sarcoma (n = 17). The tumor origins were distributed as follows: 36% extremities, 19% trunk, 15% retroperitoneal, 7% head/neck and 23% visceral. Of 228 patients who underwent surgery, 53% received surgery alone, 24% surgery and radiotherapy, 18% surgery and chemotherapy and 6% surgery, radiotherapy and chemotherapy. Besides, 21 patients did not undergo surgery due to inoperable tumor (n = 11), high age/other serious disease (n = 5), STS confirmed at autopsy (n = 3) and patient refusal (n = 2). Of these unresected patients, seven patients received chemotherapy and/or radiotherapy, whereas 14 patients received no anticancer therapy.

10.1371/journal.pone.0015368.t001

###### Prognostic relevance of clinicopathological variables for disease-specific survival in 249 non-gastrointestinal stromal tumor soft-tissue sarcomas (univariate analyses, log rank test).

![](pone.0015368.t001){#pone-0015368-t001-1}

  Characteristics                        Patients (n)   Patients (%)   Median survival (months)   5-Year survival (%)      P
  ------------------------------------- -------------- -------------- -------------------------- --------------------- ---------
  **Age**                                                                                                              
  ≤ 20 years                                  20             8                    15                      40             0.126
  21--60 years                               113             45                   68                      52           
  \>60 years                                 116             47                   30                      40           
  **Gender**                                                                                                           
  Male                                       110             44                   41                      46             0.390
  Female                                     139             56                   45                      45           
  **Patient nationality**                                                                                              
  Norwegian                                  167             67                   63                      51             0.011
  Russian                                     82             33                   22                      34           
  **Histological entity**                                                                                              
  UndifferentiatedPleomorphic sarcoma         58             23                   54                      47             0.001
  Leiomyosarcoma                              64             26                   48                      48           
  Liposarcoma                                 34             14                   NR                      67           
  Fibrosarcoma                                20             8                    44                      50           
  Angiosarcoma                                13             5                    10                      31           
  Rhabdomyosarcoma                            16             6                    17                      38           
  MPNST                                       11             4                    49                      45           
  Synovial sarcoma                            16             6                    31                      29           
  Sarcoma NOS                                 17             7                    9                       18           
  **Tumor localization**                                                                                               
  Extremities                                 89             36                  100                      53             0.348
  Trunk                                       47             29                   32                      44           
  Retroperitoneum                             37             25                   25                      38           
  Head/Neck                                   18             7                    15                      41           
  Visceral                                    58             23                   30                      42           
  **Tumor size**                                                                                                       
  ≤5 cm                                       74             30                  127                      57             0.027
  5--10 cm                                    91             37                   44                      45           
  \>10 cm                                     81             32                   28                      37           
  Missing                                     3              1                                                         
  **Malignancy grade**                                                                                                 
  1                                           61             25                   NR                      74            \<0.001
  2                                           98             39                   41                      45           
  3                                           90             36                   16                      26           
  **Tumor depth**                                                                                                      
  Superficial                                 17             7                    NR                      93            \<0.001
  Deep                                       232             93                   36                      42           
  **Metastasis at diagnosis**                                                                                          
  No                                         206             83                   76                      53            \<0.001
  Yes                                         43             17                   10                      10           
  **Surgery**                                                                                                          
  Yes                                        228             92                   59                      50            \<0.001
  No                                          21             8                    5                        0           
  **Resection margins**                                                                                                
  Wide                                       108             43                   NR                      62            \<0.001
  Non-wide/no surgery                        141             57                   21                      33           
  **Chemotherapy**                                                                                                     
  No                                         191             77                   52                      47             0.424
  Yes                                         58             23                   29                      40           
  **Radiotherapy**                                                                                                     
  No                                         176             71                   48                      46             0.590
  Yes                                         73             29                   38                      43           

Abbreviations: NR, not reached; MPNST, malignant peripheral nerve sheath tumor; NOS, not otherwise specified.

Interobserver variability {#s3b}
-------------------------

Interobserver scoring agreement was tested for one ligand (VEGF-C) and one receptor (VEGFR-3). The intraclass correlation coefficients were 0.810 for VEGF-C (P\<0.001) and 0.834 for VEGFR-3 (P\<0.001) indicating good reproducibility between the two investigating pathologists.

Expression of VEGFs/VEGFRs and their Correlations {#s3c}
-------------------------------------------------

VEGF/VEGFR expression was observed in the cytoplasm of tumor cells. For the ligand and receptor expressions we found the following correlation with malignancy grade: High VEGF-A expression, grade 1: 29%, grade 2: 48%, grade 3: 56% (P = 0.005); High VEGF-C expression, grade 1: 24%, grade 2: 41%, grade 3: 45% (P = 0.032); High VEGFR-1 expression, grade 1: 27%, grade 2: 36%, grade 3: 48% (P = 0.034); High VEGFR-2 expression, grade 1: 12%, grade 2: 27%, grade 3: 39% (P = 0.001).

Univariate Analyses {#s3d}
-------------------

[Table 1](#pone-0015368-t001){ref-type="table"} summarizes the prognostic impact of the clinicopathological variables in the total material. In the univariate analyses, patient nationality (P = 0.011), histological entity (P = 0.001), tumor size (P = 0.027), malignancy grade (P\<0.001), tumor depth (P\<0.001), metastasis at diagnosis (P\<0.001), surgery (P\<0.001) and surgical margins (P\<0.001) were all significant prognostic indicators for DSS. In the subgroup with wide resection margins (n = 108), patient nationality (P\<0.001), malignancy grade (P\<0.001), tumor depth (P = 0.009) and metastasis at diagnosis (P\<0.001) were prognostic indicators of DSS. In the subgroup with non-wide resection margins (n = 141), malignancy grade (P\<0.001), surgery (P\<0.001), metastasis at time of diagnosis (P\<0.001) and histological entity (P = 0.005) were prognostic indicators of DSS.

The influence on DSS by the VEGFs and VEGFRs are given in [Table 2](#pone-0015368-t002){ref-type="table"} and [Figure 2](#pone-0015368-g002){ref-type="fig"} (VEGF-C and VEGFR-3). In the total material, VEGF-A expression (P = 0.040) was a significant negative prognostic indicator of DSS. In the subgroup with wide resection margins, VEGF-A (P = 0.018), VEGF-C (P = 0.025) and VEGFR-3 (P = 0.027) expressions were significant negative prognostic indicators of DSS. In the subgroup with non-wide resection margins, neither the VEGFs nor VEGFRs were indicators of DSS.

![Disease-specific survival curves for VEGF-C and VEGFR-3 in the total material and in the group with wide and non-wide resection margins.\
(A) VEGF-C, total material; (B) VEGF-C, wide resection margins; (C) VEGF-C, non-wide resection margins; (D) VEGFR-3, total material; (E) VEGFR-3, wide resection margins; (F) VEGFR-3, non-wide resection margins. Abbreviations: VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.](pone.0015368.g002){#pone-0015368-g002}

10.1371/journal.pone.0015368.t002

###### Tumor expression of VEGFs and VEGFRs and their prognostic relevance for disease-specific survival in patients with non-gastrointestinal soft-tissue sarcomas in the total material (univariate analyses; log-rank test, N = 249) and in subgroups with wide and non-wide resection margins (univariate analyses; log-rank test, N = 108 and 141 respectively).

![](pone.0015368.t002){#pone-0015368-t002-2}

                 Overall material   Wide resection margins   Non-wide resection margins                                                                
  ------------- ------------------ ------------------------ ---------------------------- ---- ------- ---- ---- ----- ---- ------- ---- ---- ---- ---- -------
  **VEGF A**                                                                                                                                           
  Low                  127                    51                         59               50   0.040   57   53   NR    69   0.018   70   50   21   34   0.508
  High                 109                    44                         31               42           48   44   63    52           61   43   21   34  
  Missing               13                    5                                                        3    3                       10   7             
  **VEGF C**                                                                                                                                           
  Low                  142                    57                         59               49   0.239   62   57   NR    70   0.025   80   57   18   33   0.989
  High                  88                    35                         38               45           43   40   68    52           45   32   28   37  
  Missing               19                    8                                                        3    3                       16   11            
  **VEGF D**                                                                                                                                           
  Low                  157                    63                         57               48   0.276   64   59   NR    64   0.267   93   66   23   37   0.169
  High                  83                    33                         36               42           43   40   120   57           40   28   11   25  
  Missing               9                     4                                                        1    1                       8    6             
  **VEGFR 1**                                                                                                                                          
  Low                  145                    58                         57               48   0.262   66   61   NR    64   0.110   79   56   23   34   0.963
  High                  89                    36                         41               46           40   37   120   58           49   35   21   36  
  Missing               15                    6                                                        2    2                       13   9             
  **VEGFR 2**                                                                                                                                          
  Low                  164                    66                         57               48   0.246   80   74   NR    65   0.135   84   60   18   31   0.689
  High                  63                    25                         31               44           24   22   68    52           39   28   26   38  
  Missing               22                    9                                                        4    4                       18   13            
  **VEGFR 3**                                                                                                                                          
  Low                  148                    59                         54               48   0.275   66   61   NR    67   0.027   82   58   21   32   0.753
  High                  81                    33                         41               44           38   35   63    51           43   31   23   37  
  Missing               20                    8                                                        34   4                       16   11            

Abbreviations: NR, not reached.

Multivariate Cox Proportional Hazards Analysis {#s3e}
----------------------------------------------

Results of the multivariate analyses are presented in [Tables 3](#pone-0015368-t003){ref-type="table"} and [4](#pone-0015368-t004){ref-type="table"}. In the total material, tumor depth (P = 0.046), tumor size (P = 0.045), high malignancy grade (P\<0.001), lack of surgery (P\<0.001), non-wide resection margins (P = 0.004) and metastasis at diagnosis (P\<0.001), but none of the angiogenic markers, were significant independent prognostic indicators of DSS ([Table 3](#pone-0015368-t003){ref-type="table"}). In the wide resection margins group, Russian nationality (P = 0.013), high malignancy grade (P = 0.009), metastasis at diagnosis (P = 0.007) and high VEGFR-3 expression (P = 0.042, HR = 1.907, 95% CI 1.024-3.549) were significant independent prognostic indicators for reduced DSS ([Table 4](#pone-0015368-t004){ref-type="table"}). In the group with non-wide resection margins, high malignancy grade (P\<0.001), lack of surgery (P\<0.001) and metastasis at time of diagnosis (P\<0.001) were independent prognostic indicators of poor DSS.

10.1371/journal.pone.0015368.t003

###### Results of the Cox regression analysis of the total material.

![](pone.0015368.t003){#pone-0015368-t003-3}

  Factor                                 Hazard Ratio      95% CI                          P
  ------------------------------------- -------------- --------------- ------------------------------------------
  **Tumor depth**                                                      
  Superficial                               1.000                      
  Deep                                      7.541       1.040--54.661                    0.046
  **Tumor size**                                                         0.045[\*](#nt103){ref-type="table-fn"}
  ≤5 cm                                     1.000                      
  5--10 cm                                  1.420       0.895--2.252                     0.136
  \>10 cm                                   1.858       1.140--3.030                     0.013
  **Malignancy grade**                                                  \<0.001[\*](#nt103){ref-type="table-fn"}
  1                                         1.000                      
  2                                         2.892       1.660--5.040                    \<0.001
  3                                         4.192       2.421--7.259                    \<0.001
  **Surgery**                                                          
  Yes                                       1.000                      
  No                                        8.426       4.311--16.469                   \<0.001
  **Resection margins**                                                
  Wide                                      1.000                      
  Non-wide                                  1.785       1.209--2.637                     0.004
  **Metastasis at time of diagnosis**                                  
  No                                        1.000                      
  Yes                                       2.551       1.672--3.893                    \<0.001

\*Overall significance as a prognostic factor.

10.1371/journal.pone.0015368.t004

###### Results of the Cox regression analysis among patients with wide resection margins.

![](pone.0015368.t004){#pone-0015368-t004-4}

  Factor                                 Hazard Ratio      95% CI                         P
  ------------------------------------- -------------- --------------- ----------------------------------------
  **Patient nationality**                                              
  Norwegian                                 1.000                      
  Russian                                   2.257       1.186--4.295                    0.013
  **Malignancy grade**                                                  0.009[\*](#nt104){ref-type="table-fn"}
  1                                         1.000                      
  2                                         3.672       1.200--11.240                   0.023
  3                                         5.484       1.828--16.447                   0.002
  **Metastasis at time of diagnosis**                                  
  No                                        1.000                      
  Yes                                       2.900       1.332--6.315                    0.007
  **VEGFR-3**                                                          
  Low                                       1.000                      
  High                                      1.907       1.024--3.549                    0.042

\*Overall significance as a prognostic factor.

Discussion {#s4}
==========

In this study we observed that high expression of VEGFR-3 was a significant independent negative prognostic indicator of DSS in non-GIST STS patients with wide resection margins. Although there have been prior evaluations of the VEGF axis in STSs, these have primarily been focused on VEGF-A. Herein, we have presented a large-scale study of the prognostic impact of VEGF-A, -C and -D and VEGFR-1-3 in non-GIST STS patients. To our knowledge, this is the first evaluation of these pathways according to resection margins.

The major weakness of this study, normally seen in sarcoma studies in general, is the heterogeneity of the sarcoma population. Even with a relatively large sample cohort with regard to non-GIST STSs, the numbers are too small to do meaningful explorations according to histological subgroups, at least with respect to multivariate analysis.

Wide resection margins have been demonstrated to give the best overall survival, with more modest results for marginal and particularly intralesional resections [@pone.0015368-Dickinson1]. Despite wide resection margins 40% of patients in our population succumbed to their sarcoma within five years. Identification of prognostic markers within this group of patients is therefore of great interest.

This is the first report of VEGFR-3 expression being an independent negative prognostic marker in non-GIST with wide resection margins. VEGFR-3 is a tyrosine-kinase receptor that is activated by VEGF-C and -D. The VEGFR-3/VEGF-C/-D system is considered the main pathway responsible for developing lymphatic vessels [@pone.0015368-Tammela1]. During the organogenesis, VEGFR-3 is expressed in all endothelia, but as the organism matures the expression has been associated mainly with lymphangiogenesis [@pone.0015368-Kaipainen1]. In a small series of 32 STSs, Friedrichs et al. found that around 50% of the tumors contained confirmable lymphatic vessels and expressed VEGFR-3 and VEGF-C [@pone.0015368-Friedrichs1]. In contrast, recent data have shown that VEGFR-3 is expressed in the lamellopodia of lead-cells in angiogenic sprouts, indicating that VEGFR-3 may play an important role also in angiogenesis [@pone.0015368-Tammela2]. This has been further supported by the fact that co-administration of VEGFR-2 and VEGFR-3 antibodies lead to a more extensive suppression of angiogenesis than VEGFR-2 antibodies alone [@pone.0015368-Tammela2]. Through Folkman\'s work on angiogenesis we know that without blood-supply a tumor cannot grow beyond 1--2 mm^3^ in size [@pone.0015368-Folkman1]. This means that the angiogenic capabilities of VEGFR-3 may be driving tumor angiogenesis and ultimately tumor development in non-GIST STS patients. As the vascular and not the lymphatic system is the principal metastatic pathway in non-GIST STSs, it is natural to assume that increased angiogenesis will augment the risk for metastasis development [@pone.0015368-Leong1]. Increased vascularity will also lead to increased interstitial fluid pressure (IFP), which inhibits drug delivery to the tumor [@pone.0015368-Heldin1]. Since VEGFR-3 is a strong lymphangiogenic factor, one could assume a worse DSS mediated by high expression levels of VEGFR-3 was due to increased lymphangiogenesis and subsequent lymph node metastasis, although this is rare for sarcomas [@pone.0015368-Leong1], [@pone.0015368-Achen1]. VEGFR-3 may also function as a transducer of survival signals through autocrine pathways with tumor-derived VEGF-C or -D or autoactivation of the receptor itself [@pone.0015368-Tammela1].

In the presented population with wide resection margins, tumor VEGF-C expression was a significant negative prognostic marker for DSS. To our knowledge, only one small study has previously reported on this relationship in STSs. In 45 patients with undifferentiated pleomorphic sarcoma (previously malignant fibrous histiocytoma, MFH) and neurogenic sarcoma, Hoffmann et al. concluded surprisingly that high expression of VEGF-C mRNA led to a longer overall survival [@pone.0015368-Hoffmann1]. This is inconsistent with our findings and may be explained by sampling variation or lacking translation of mRNA to protein in the tumors. VEGF-C can interact with both VEGFR-2 and VEGFR-3, leading to migration of ECs and increased capillary permeability [@pone.0015368-Tammela1], [@pone.0015368-Adams1]. These effects are thought to be mediated through VEGFR-2 in vascular ECs and through VEGFR-3 in lymphatic ECs [@pone.0015368-Tammela1], [@pone.0015368-Adams1]. In tumors this will lead to angiogenesis, lymphangiogenesis and increased IFP, which promote tumor sustenance, progression, metastasis and resistance to cytotoxic therapy.

We found VEGF-A expression in tumor tissue to be a significant negative prognostic marker for DSS in univariate analyses, both in the total material and in the subgroup with wide resection margins. Further, we found that VEGF-A and its corresponding receptors VEGFR-1 and -2, showed significant correlations with histological tumor grade, in accordance with previously published studies [@pone.0015368-Chao1], [@pone.0015368-Yudoh1], [@pone.0015368-DuBois1]. VEGF-A activation of its corresponding receptors, VEGFR-1 and -2, is known to be the major angiogenic pathway [@pone.0015368-Tammela1]. The close correlation between these markers and histological grade suggests that they play a role in the development of many of the non-GIST STSs, either through angiogenesis or other stroma-associated mechanisms.

Antibodies targeting the VEGF/VEGFR systems are readily available, and clinical trials with such agents have been initiated in several cancer types [@pone.0015368-Ribatti1]. However, proper criteria for selecting patients to treatment with these drugs are still lacking [@pone.0015368-Ribatti1]. For the employment of antiangiogenic drugs, side effects have to be carefully weighed against efficacy, especially for patients with intermediate to good prognosis. Hence, enhanced knowledge about these molecules and their impact on different types of cancer is pivotal.

As our data are prognostic and not mechanistic we cannot conclude on which pathways are operative in non-GIST STSs expressing VEGFs and VEGFRs. Nevertheless, it can be deduced that VEGFs and VEGFRs play critical roles in sarcoma progression and prognosis. But whether angiogenic ligands and receptors may have predictive effects with respect to therapy remains unanswered. The mechanistic impacts of angiogenesis, lymphangiogenesis, autocrine versus paracrine pathways as well as the relevance of constitutively activated receptors have to be further clarified. Consequently, future translational research in this field is needed.
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